Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

Exenatide, recently developed for treatment of type 2 diabetes, induces appetite suppression and weight loss with common side effects.

Who Took Part

According to the abstract, 11 patients were involved.

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled, crossover and pilot study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Only one side, usually the patients, was kept unaware of whether Exenatide was given.

A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Appetite, Blood Glucose, Eating, Energy Metabolism, Exenatide, Gastrointestinal Hormones and Homeostasis.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Exenatide in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 13 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exenatide compound page, all human trials.